Lauren Orenstein, MD
Dermatology · Atlanta, GANPI 1457790529
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $48,148 of the $51,718 with a category attached, or 93.1%. 4 manufacturers reported payments, led by UCB, Inc. at 56.0% of the total. 2025 is the largest year on record at $23,983, 6.4 times the $3,750 reported in 2021. Among dermatology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 44 payments — averaging $1175.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$29K
- Sanofi Pasteur Inc.$9K
- Incyte Corporation$8K
- Novartis$5K
Across 37 payments — averaging $2813.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$100K
- Incyte Corporation$4K
What the payments were for
- Consulting fees$48,14893%
- Travel & lodging$2,7445%
- Food & beverage$8262%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 24 | $28,985 |
| Sanofi Pasteur Inc. | 2 | $9,380 |
| Incyte Corporation | 9 | $7,904 |
| Novartis | 9 | $5,448 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$51,718 in reported general payments places this provider in the 90th percentile of 345 dermatology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 18 | $347,539 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 30 | $308,676 |
| InflectraInfliximab-Dyyb | 18 | $198,154 |
| Dupixent PenDupilumab | 22 | $81,574 |
| Doxycycline Monohydrate | 19 | $874 |
| Clindamycin Phosphate | 13 | $302 |
| Prednisone | 13 | $5 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Atlanta
- Zakiya RiceAtlanta$1.1M
- Joseph PayneAtlanta$711K
- Jamie WeismanAtlanta$620K
- Mack RachalAtlanta$260K
- Sumayah TaliaferroAtlanta$104K
- Sarah ChisolmAtlanta$59K
- Anna PareAtlanta$58K
- Chelsie RogersAtlanta$43K
- Ron FeldmanAtlanta$29K
- Christine LawAtlanta$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.